These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 8835820)

  • 1. Alterations of p16/CDKN2, p53 and ras genes in oral squamous cell carcinomas and premalignant lesions.
    Matsuda H; Konishi N; Hiasa Y; Hayashi I; Tsuzuki T; Tao M; Kitahori Y; Yoshioka N; Kirita T; Sugimura M
    J Oral Pathol Med; 1996 May; 25(5):232-8. PubMed ID: 8835820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas.
    Tsuzuki T; Tsunoda S; Sakaki T; Konishi N; Hiasa Y; Nakamura M
    Cancer; 1996 Jul; 78(2):287-93. PubMed ID: 8674005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations of tumor suppressor genes and the H-ras oncogene in oral squamous cell carcinoma.
    Sakata K
    J Oral Pathol Med; 1996 Jul; 25(6):302-7. PubMed ID: 8887073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder.
    Gonzalez-Zulueta M; Shibata A; Ohneseit PF; Spruck CH; Busch C; Shamaa M; El-Baz M; Nichols PW; Gonzalgo ML; Elbaz M [corrected to El-Baz M]
    J Natl Cancer Inst; 1995 Sep; 87(18):1383-93. PubMed ID: 7658499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P53 expression, p53 and Ha-ras mutation and telomerase activation during nitrosamine-mediated hamster pouch carcinogenesis.
    Chang KW; Sarraj S; Lin SC; Tsai PI; Solt D
    Carcinogenesis; 2000 Jul; 21(7):1441-51. PubMed ID: 10874024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 gene mutations in sequential oral epithelial dysplasias and squamous cell carcinomas.
    Shahnavaz SA; Regezi JA; Bradley G; Dubé ID; Jordan RC
    J Pathol; 2000 Mar; 190(4):417-22. PubMed ID: 10699989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High frequency of homozygous deletion and methylation of p16(INK4A) gene in oral squamous cell carcinomas.
    Nakahara Y; Shintani S; Mihara M; Ueyama Y; Matsumura T
    Cancer Lett; 2001 Feb; 163(2):221-8. PubMed ID: 11165758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of p16/CDKN2 alterations in thyroid carcinomas.
    Yane K; Konishi N; Kitahori Y; Naito H; Okaichi K; Ohnishi T; Miyahara H; Matsunaga T; Hiasa Y
    Cancer Lett; 1996 Mar; 101(1):85-92. PubMed ID: 8625287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infrequent Ha-ras mutations and absence of Ki-ras, N-ras, and p53 mutations in 4-nitroquinoline 1-oxide-induced rat oral lesions.
    Suzui M; Yoshimi N; Tanaka T; Mori H
    Mol Carcinog; 1995 Dec; 14(4):294-8. PubMed ID: 8519419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of CDKN2A gene loss in sequential oral epithelial dysplasias and carcinomas.
    Shahnavaz SA; Bradley G; Regezi JA; Thakker N; Gao L; Hogg D; Jordan RC
    Cancer Res; 2001 Mar; 61(6):2371-5. PubMed ID: 11289098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage.
    Nakagawa K; Conrad NK; Williams JP; Johnson BE; Kelley MJ
    Oncogene; 1995 Nov; 11(9):1843-51. PubMed ID: 7478613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deletion analysis of the p16/CDKN2 gene in head and neck squamous cell carcinoma using quantitative polymerase chain reaction method.
    Rawnsley JD; Srivatsan ES; Chakrabarti R; Billings KR; Wang MB
    Arch Otolaryngol Head Neck Surg; 1997 Aug; 123(8):863-7. PubMed ID: 9260553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low frequency of p16/CDKN2 gene mutations in esophageal carcinomas.
    Esteve A; Martel-Planche G; Sylla BS; Hollstein M; Hainaut P; Montesano R
    Int J Cancer; 1996 May; 66(3):301-4. PubMed ID: 8621247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers.
    Kersting M; Friedl C; Kraus A; Behn M; Pankow W; Schuermann M
    J Clin Oncol; 2000 Sep; 18(18):3221-9. PubMed ID: 10986054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The p53 tumor-suppressor gene and ras oncogene mutations in oral squamous-cell carcinoma.
    Sakai E; Rikimaru K; Ueda M; Matsumoto Y; Ishii N; Enomoto S; Yamamoto H; Tsuchida N
    Int J Cancer; 1992 Dec; 52(6):867-72. PubMed ID: 1459726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between polymorphism in p21(Waf1/Cip1) cyclin-dependent kinase inhibitor gene and human oral cancer.
    Ralhan R; Agarwal S; Mathur M; Wasylyk B; Srivastava A
    Clin Cancer Res; 2000 Jun; 6(6):2440-7. PubMed ID: 10873097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 mutations and clonality in vulvar carcinomas and squamous hyperplasias: evidence suggesting that squamous hyperplasias do not serve as direct precursors of human papillomavirus-negative vulvar carcinomas.
    Kim YT; Thomas NF; Kessis TD; Wilkinson EJ; Hedrick L; Cho KR
    Hum Pathol; 1996 Apr; 27(4):389-95. PubMed ID: 8617483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coincidental alterations of p16INK4A/CDKN2 and other genes in human lung cancer cell lines.
    Fujishita T; Mizushima Y; Kashii T; Kobayashi M
    Anticancer Res; 1998; 18(3A):1537-42. PubMed ID: 9673367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 aberrations in oral submucous fibrosis and oral squamous cell carcinoma detected by immunocytochemistry and PCR-SSCP.
    Trivedy C; Warnakulasuriya KA; Tavassoli M; Steingrimsdottir H; Penhallow J; Maher R; Johnson NW
    J Oral Pathol Med; 1998 Feb; 27(2):72-7. PubMed ID: 9526733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of p53/BAX/p16(ink4a/CDKN2) in esophageal squamous cell carcinoma: high BAX and p16(ink4a/CDKN2) identifies patients with good prognosis.
    Sturm I; Petrowsky H; Volz R; Lorenz M; Radetzki S; Hillebrand T; Wolff G; Hauptmann S; Dörken B; Daniel PT
    J Clin Oncol; 2001 Apr; 19(8):2272-81. PubMed ID: 11304781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.